

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

#### Listing of Claims:

1 to 70. (Cancelled)

71. (Previously presented): A composition containing a nucleic acid encoding a polypeptide consisting of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

72. (Previously presented): A composition containing a nucleic acid encoding a polypeptide that comprises the sequence of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

73. (Previously presented): A composition containing a nucleic acid that encodes a polypeptide comprising a sequence at least 98% identical to the 1132 residues of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

74. (Previously presented): A composition containing a nucleic acid encoding a polypeptide consisting of at least 10 contiguous amino acids of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

75. (Cancelled)

76. (Previously presented): A composition containing a nucleic acid encoding a polypeptide that comprises at least 10 contiguous amino acids of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTRT (SEQ. ID NO:2) when administered to a subject.

77. (Previously presented): A composition containing a nucleic acid encoding a polypeptide selected from:

- (a) the amino acid sequence SEQ ID NO:2; and,
- (b) an immunogenic fragment of SEQ ID NO:2,

wherein the composition, when administered to a subject, induces an adaptive immune response against hTERT (SEQ ID NO:2).

78. (Cancelled)

79. (New): A composition containing a plasmid vector encoding a polypeptide that comprises the sequence of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTERT (SEQ. ID NO:2) when administered to a subject.

80. (New): A composition containing a plasmid vector encoding a polypeptide that comprises at least 10 contiguous amino acids of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTERT (SEQ. ID NO:2) when administered to a subject.

81. (New): A composition containing a plasmid vector encoding a polypeptide comprising a sequence identical to the 1132 residues of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTERT (SEQ. ID NO:2) when administered to a subject.

82. (New): A composition containing a plasmid vector encoding a polypeptide comprising a sequence at least 98% identical to the 1132 residues of SEQ. ID NO:2, wherein the composition elicits an adaptive immune response against hTERT (SEQ. ID NO:2) when administered to a subject.